In this issue of the journal, Kobelt et al. 1 present an updated picture of their work from 2006 on the burden and economic cost of multiple sclerosis (MS)related disability in Europe. 2 The latest study, which involves close to 17,000 people with MS (pwMS) from 16 European countries, is the largest and most extensive to date. As always the figures never fail to shock and are a stark reminder of just how high the mountain is that we need to climb, if we want to reduce the burden of MS for the individual with the disease, their families and society in general. If you are involved with treating MS, this paper is an essential read; the data are indispensable for making the case for improving MS services across Europe, for reiterating the case for early and effective treatment in MS 3 and to support much needed research into MS prevention. 4 Despite its failings, 5 the Expanded Disability Status Scale (EDSS) remains the bedrock for assessing disability in MS. Although this study used a self-assessed EDSS, it is clear that the link between loss of utility, or quality of life, and economic costs of MS are strongly associated with disability. This study confirms other studies that show that society rates pwMS with an EDSS greater than 8.0 as having a quality of life worse than death (negative utility score). 6 To the best of my knowledge, there is no other chronic disease with negative utility scores and demonstrates just how bad the general public's perception is of MS.
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Costs related to disability increase with worsening disability, or EDSS, but not in a linear fashion. Disability-related costs increase gradually from EDSS 0.0 to 4.0, are then relatively constant to EDSS 6.0, before increasing substantially from EDSS 7.0. There is a clear inflection in disability-related costs above EDSS 7.0 when pwMS start to lose upper limb function and hence their independence. The significance of these observations cannot be overstated in that all MS disease-modifying therapies (DMTs) have only been licensed for pwMS who are mobile (EDSS < 7.0) and have relapsing forms of the disease. Another shocking statistic, which is not too dissimilar to their earlier findings, is the observation that by EDSS 3.5 approximately 50% of pwMS are unemployed. This high rate of unemployment is occurring at a level of disability, which is typically not associated with overt physical disability as measured using the EDSS, but by neurological impairments not detected on the standard neurological examination. 7 Reasons for the high unemployment at low levels of physical disability relate to hidden symptoms and impairments in particular cognitive impairment, cognitive fatigue, anxiety and depression. This survey highlights the impact of fatigue and cognitive difficulties on productivity at work. Fatigue and difficulty thinking were much more common than mobility issues as a cause of work-related problems in the participants who were working. 2 These 'hidden impairments' stress the importance of targeting MS-related disability as early as possible in the course of the disease. 8 The mean annual cost per patient is an interesting metric and shows that at low disabilities it is dominated by the cost of DMTs, but with increasing disability services, informal care and production loss dominate. What this study cannot show is whether, or not, the investment in high-cost DMTs early in the course of the disease prevents these indirect costs later in the course of the disease. The assumption is that if DMTs prevent or delay the onset of more advanced MS, then the upfront drug costs would be justified. This is what Health Technology Assessments (HTAs) try to model using relatively limited data from pivotal DMT registration trials. However, some would argue that the high costs of DMTs, currently being charged, are simply not cost-effective. 9, 10 The stand out figure for me is the amount of informal care that is required to look after people with more advanced MS, or severe disability, across Europe. In the majority of countries, this is more than 150 hours a month, which is more than a full-time staff equivalent. This figure underlines the high indirect costs associated with MS and the impact it has on partners and family members.
The study also highlights wide variations in the proportion of study subjects on DMTs across Europe. Marziniak et al. 11 have recently argued that there are numerous factors at play, including economic and cultural factors, and as a consequence of this disparity, pwMS may not be receiving the appropriate therapy at the correct time. One potential solution would be the development of a European treatment guideline that could be used to inform, and be informed by, national policies, to help disseminate best clinical practice. 11, 12 Although the shortcomings of this study are numerous, they don't detract from the core messages. The populations of subjects from the different countries participating in this study were not uniform. For example, study participants from the United Kingdom tended to have more advanced disease with average age of 57 years and a mean EDSS of 5.5; in comparison, at the other end of the spectrum, Russian participants had an average age of 38 years and a mean EDSS of 2.9. The study did not explore the impact of national and regional guidelines on MS care, or cultural factors such as family values and traditions that would clearly affect the interpretation of many of the metrics that were assessed in this study.
In conclusion, MS is a disabling disease that is associated with reduced quality of life and a very high socioeconomic impact. The economic cost of MS is largely driven by indirect costs that are linked to early, and very high, unemployment rates in pwMS. The costs increase dramatically with more severe disability, in particular when patients lose their upper limb function and independence. The wide variation in practice and potential outcomes across countries, which have been identified by this study, highlight the need for political intervention at a European level. What is urgently needed are longitudinal data to assess whether early intervention with DMTs, particularly with the newer generation, more effective DMTs, improves MS outcomes in the long term.
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